FURUNO-ELECTRIC
20.8.2024 06:01:33 CEST | Business Wire | Press release
Furuno Electric is delighted to announce that the company will participate in Jammertest 2024 in Andøya, Norway from 9 to 13 September.
The participants will test GNSS receivers in an environment where they will actually be exposed to jamming and spoofing* signals and obtain data on their tolerance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819796325/en/
Jammertest 2024 (Graphic: Business Wire)
About Jammertest
This Jammertest is the world's largest test event where resistance to jamming and spoofing can be tested in a real environment. It is organized by the Norwegian Public Roads Administration, Norwegian Communications Authority, Norwegian Defence Research Establishment, Norwegian Metrology Service, Norwegian Space Agency and Testnor.
Jamming has actually been detected in the Black Sea, Northern Europe, and the Middle East, and there is a growing need for enhanced resiliency in critical infrastructure such as traffic control and mobile communications. Furuno has been testing its receivers by creating signals that simulate jamming and spoofing in a lab environment, but to verify and improve our anti-jamming capabilities, it is ideal to perform a variety of evaluations in a real environment. To allow participating companies and institutions to test their GNSS receiver-equipped products in a real-world environment, the organizer will conduct various types of jamming and spoofing attacks during the event.
The resistance test Furuno will carry out
In this Jammertest, Furuno will test the jamming and spoofing resistance of GT-100 which is Furuno’s timing multi-GNSS receiver module that supports dual-frequency band reception in the L1 and L5 bands. GNSS receivers for time synchronization are used in critical infrastructures that require robustness, such as 5G mobile base stations, TV broadcasting, financial institutions, and power grids. The latest product, GT-100, can automatically mitigate the effects of jamming and spoofing signals while providing users with real-time notification of the jamming signal frequency and signal strength. Also, if it completely loses reception of the L1 band signal, it can still maintain reception of the L5 band signal and continuously output stable time.
By participating in the Jammertest 2024, Furuno will evaluate and analyze the level of resistance of GT-100 to jamming and spoofing in real-world environments and use the results to further improve its robustness.
About Jammertest 2024
Official name of the event: Jammertest 2024
Event dates: September 9 - 13, 2024
Location: Andøya, Norway
Official website: https://jammertest.no/jammertest/
Products Tested
Timing Multi-GNSS Receiver Module GT-100
https://www.furuno.com/en/products/gnss-module/GT-100
Multi-GNSS Timing Antennas AU-500
https://www.furuno.com/en/products/gnss-antenna/AU-500
* Jamming and Spoofing: Jamming means radio waves that interfere with GNSS signals. Spoofing means that malicious actors intentionally mimic and broadcast GNSS-like signals with the intent to trick nearby GNSS receivers into calculating incorrect position and/or time.
Related Links
Announced on May 16, 2023: Furuno Announces High-Performance Multi-GNSS Timing Antennas
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1320&dispmid=961
Announced on September 14, 2022: Furuno Announces Most Advanced Global Timing Solutions Supporting L1 and L5 GNSS Signals
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1216&dispmid=961
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819796325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom